ZYGOMATIC IMPLANTS MAY IMPROVE QUALITY OF LIFE AND SATISFACTION IN PATIENTS WITH ATROPHIED MAXILLA.

ARTICLE TITLE AND BIBLIOGRAPHIC INFORMATION: Alberto J, Mariano S, Guerrero-s Y, Pato-mourelo J. Evaluation of Quality of Life And Satisfaction in Patients with Fixed Prostheses on Zygomatic Implants Compared with the All-on-Four Concept: A Prospective Randomized Clinical Study. Int J Environ Res Public Heal. 2021; 18(3426). SOURCE OF FUNDING: The Department of Oral Surgery, University of Murcia, Murcia, Spain. TYPE OF STUDY/DESIGN: Prospective randomized clinical trial.

Limited Evidence Suggests That, in a Deficient Edentulous Posterior Maxilla, Short Implants Could Be an Alternative to Sinus Augmentation With Longer Implants.

ARTICLE TITLE AND BIBLIOGRAPHIC INFORMATION: Short dental implants as compared to maxillary sinus augmentation procedure for the rehabilitation of edentulous posterior maxilla: Three-year results of a randomized clinical study. Taschieri S, Lolato A, Testori T, Francetti L, Del Fabbro M. Clin Implant Dent Relat Res 2018;20:9-20. SOURCE OF FUNDING: None. TYPE OF STUDY/DESIGN: RCT with a parallel group design.

Probiotic administration and the incidence of nosocomial infection in pediatric intensive care: a randomized placebo-controlled trial.

OBJECTIVE: To evaluate the efficacy of probiotics in reducing the rates of nosocomial infection in pediatric intensive care. DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING: A 16-bed pediatric intensive care unit in a university-affiliated children's hospital. PATIENTS: Sixty-one pediatric patients were enrolled from April 2004 until December 2004. Screening of all patients admitted occurred on a daily basis. Patients were excluded if they had the following: evidence/suspicion of intestinal perforation, evidence/suspicion of mechanical gastrointestinal obstruction, absolute neutrophil count

ROLE OF T REGULATORY CELLS IN CHRONIC HCV INFECTED EGYPTIAN PATIENTS AND THEIR IMPACT ON THE RESPONSE TO PEGYLATED INTERFERON THERAPY.

Treatment of patients with chronic hepatitis C with the current standard pegylated interferon (PEG-IFN) and ribavirin achieves overall response (SVR) rates of ~55%. A role of CD4+ CD25+ regulatory T cells (Treg cells) has been proposed as they can suppress HCV-specific T cells in HCV-infected patients. Patients with chronic HCV legible for PEG-IFN plus ribavirin treatment, were classified according to their response to treatment into two groups (responders and non-responders, 32 and 27 patients respectively). Blood and plasma samples were collected at the start of treatment and at 12 and 24 weeks during treatment. Immunophenotyping by flow cytometry for Treg cells, the FOXP-3 expression using real-time PCR and measurement of IL-10, TGF-ß CXCL-9 and CXCL-10 were performed. Increased expression of Treg cells was detected in patients who didn't respond to treatment before and during treatment. Also, the levels of IL-10, TGF-ß, CXCL-9 and CXCL-10 revealed significant increase.in non-responders all through compared to responders group. Evaluation of Treg cells, cytokines (IL-10 & TGF-ß) and chemokines (CXCL-9 & CXCL-10) before starting the treatment could be a predictor of response to treatment with PEG-IFN plus ribavirin. The optimum levels which would differentiate between responders and non-responders are needed to be defined before-hand.